Read this first: This is a rat study of streptozotocin-induced diabetes and heart damage. It is not human evidence, and it does not show that glycine, NAC or any supplement protects people's hearts.
A glycine-plus-NAC combination, the same pairing behind the supplement trend known as GlyNAC, helped diabetic rats hold on to healthier heart tissue. But the researchers say the combo didn't win every round. NAC alone beat it on some measures.
The work comes from a team at the University of Sarajevo and Cantonal Hospital Zenica, published in Pathophysiology in 2026.
What the researchers actually tested
Diabetic cardiomyopathy is heart muscle damage driven by diabetes. It is linked to oxidative stress, inflammation and fibrosis, the stiffening, scar-like buildup of connective tissue. The team focused on the IL-33/sST2 signaling axis, which has emerged as a regulator of cardiac remodeling. Soluble ST2 (sST2) is a circulating marker tied to that process.
The design was simple:
- 34 adult Wistar rats were split into five groups.
- The groups were healthy controls, untreated diabetic rats, and diabetic rats given NAC (100 mg/kg/day), glycine (250 mg/kg/day), or both.
- Diabetes was induced with a single injection of streptozotocin (55 mg/kg).
- Treatment lasted 12 weeks.
The researchers measured serum sST2, IL-33, malondialdehyde (MDA, an oxidative-stress marker) and superoxide dismutase (SOD) activity. They also examined heart tissue with stereological and histopathological analyses.
The damage diabetes did
Untreated diabetic rats had significantly higher serum sST2, IL-33 and MDA. Their hearts showed marked remodeling:
- expansion of the interstitial and perivascular compartments
- increased connective tissue deposition
- reduced cardiomyocyte volume density, meaning less of the heart was made of working muscle cells
In plain terms, the diabetic hearts were becoming more scarred and less muscular.
The striking finding: the combo and heart structure
Both NAC and glycine, given alone, significantly reduced these biochemical and structural abnormalities compared with untreated diabetic animals. The combination stood out on two fronts. It produced particularly pronounced reductions in sST2 and IL-33. It was also associated with preservation of myocardial architecture, the tissue-structure outcome closest to the scarring-type remodeling that defines the condition.
That is why the combination is the headline. On the structural and signaling measures the authors emphasize, the pairing looked especially favorable in these rats.
The catch: it wasn't a clean sweep
The authors explicitly avoid claiming the combo was better at everything. Treatment effects "varied across outcomes," and some oxidative-stress parameters improved more with NAC alone. The paper says its findings highlight potentially complementary actions of the two compounds "without implying uniform superiority of the combined regimen."
NAC is a precursor to cysteine, and glycine is the other building block of glutathione, so the two may play different roles. The paper frames this only as complementary actions, and it did not test a mechanism that explains the differences.
How this connects to human GlyNAC research
GlyNAC has drawn attention because human studies, mostly small ones in older adults and other specific groups, have explored whether it improves glutathione status and oxidative-stress markers. This rat paper is not part of that human evidence base. It adds a lab-animal signal in a different setting, diabetes-related heart remodeling. The authors describe it as "an experimental basis for further investigation," which is about as far as the data can go.
Why rat mg/kg doses don't translate to people
The doses above are rat doses, and you can't simply scale them to a human by body weight.
- Rats and humans differ in metabolism, absorption and body-surface-area scaling.
- The study used a chemically induced diabetes model that doesn't mirror the way type 2 diabetes develops in people.
- It reports no human dosing, safety or long-term outcome data.
No human dose can be derived from this paper, and this article doesn't suggest one.
Practical takeaways
1. Treat it as a hypothesis. The study suggests glycine and NAC deserve further research in diabetic heart disease. It doesn't show they prevent or treat it in people.
2. Who might care. People with blood sugar issues, prediabetes or diabetes may be curious about GlyNAC. If that's you, talk to your doctor before adding supplements. Don't substitute them for prescribed diabetes or heart care.
3. NAC cautions. NAC can cause side effects such as nausea or other stomach upset in some people, and allergic-type reactions are possible. It can interact with certain medications, so check with a clinician or pharmacist, especially if you take heart medications, have asthma, are pregnant or breastfeeding, or have other medical conditions.
4. Don't overread small-animal data. This study used 34 rats. Whether the combined regimen's benefits hold up over time, in different models or in humans is unknown.
Bottom line
In diabetic rats, glycine plus NAC gave the strongest showing on sST2, IL-33 and preserving heart structure. NAC alone sometimes did better on oxidative-stress markers. That makes it an intriguing preclinical lead for GlyNAC, not a recommendation. Until controlled human studies test diabetic heart outcomes, the safest conclusion is that this is a promising rat finding that needs follow-up.